Business Wire

Ricardo Air Quality and Economic Expertise to Help European Commission Reduce Hundreds of Thousands of Premature Deaths From Air Pollution

Share

Ricardo, a global strategic environmental and engineering consulting company, has significantly contributed to the European Commission’s revision of the Ambient Air Quality Directive which sets air quality standards for European Union Member States. This Directive underpins the improvement of air quality to reduce the 300,000 premature deaths a year and a significant number of noncommunicable diseases such as asthma, cardiovascular problems and lung cancer, which are still attributed to air pollution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221114005544/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Smog in the city of Milan, Italy (Photo: Business Wire)

Led by Ricardo, a team of air quality experts, including IIASA, Met.No, VITO and Trinomics, carried out an impact assessment into options to revise the legislation. Using scenario modelling to 2050, Ricardo considered what the potential impacts of the new air quality standards could be in relation to public health, the environment and business. Ricardo provided economic expertise to the impact assessment which shows that the benefits of the proposed revision for society far outweigh the costs. The main benefits expected are related to health: including reduced mortality and morbidity, reduced healthcare expenditure, reduced absence from work due to illness and increased productivity at work. Additionally, key benefits for the environment include reduced ozone-related crop yield losses.

A further study, also led by Ricardo, set out suggestions to improve support for local authorities in achieving cleaner air through strengthening air quality monitoring, modelling and plans.

Dr Beth Conlan, Technical Director – Air Quality at Ricardo said: “Ricardo has the longest-established specialist air quality team in the world and, with over 130 experts, one of the largest, and this is reflected in the UK’s position as a world-leader in air quality expertise. As our corporate mission is to create a safe and sustainable world, we are honoured that the European Commission chose to entrust this seminal project to us, which will significantly reduce deaths, improve people’s quality of life and public health in general. Legislation really does push forward change and, in my thirty years of working in this sector, this regulatory revision is likely to be the most far reaching and valuable in terms of improving air quality.”

Ricardo has provided expertise to the European Union (EU) in air quality and climate change since the 1990s, supporting the EU’s drive to lower emissions, through the Green Deal, and air quality directives – the last one of which was enacted in 2008. Ricardo’s air quality team has very well-established capability in air quality assessment and management practice. It was this capability, together with Ricardo’s economic expertise and proven track record in successfully delivering co-beneficial air quality and climate change programmes for the European Commission that led to the Ricardo-managed air quality team working on this project.

In the UK, Ricardo’s air quality expertise is helping the national Government shape strategies that offer routes to delivering national emissions reduction commitments such as the UK’s Clean Air Strategy, the National Air Pollution Control Plan, National Emission Ceilings targets, Environment Act Air Quality targets, and the UK’s net zero strategy, as well as international objectives through the Gothenburg Protocol.

Ends

About Ricardo

Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contacts:
Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carbios Hosts World’s First PET Biorecycling Summit with Bertrand Piccard, Initiator and Chairman of the Solar Impulse Foundation, as Keynote Speaker9.12.2022 08:45:00 EET | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005776/en/ Bertrand Piccard, Initiator and Chairman of the Solar Impulse Foundation, as Keynote Speaker at the First World PET Biorecycling Summit organised by Carbios Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, hosted the world’s first PET Biorecycling Summit from 7 to 8 December 2022 in Paris. The event attracted over 100 international participants from the scientific, academic, and industrial worlds to exchange on the advances in the field of biological recycling, and how to bring these innovations for a circular economy to market. The two-day conference gathered world-renowned scientists from various academic institutions to share their latest research on PET enzymatic depolymerization. Bertrand Piccard, Initiator and Chairman

Crash Bandicoot Returns in All-new Team Based, Four vs. Four, Competitive Showdown, Crash Team Rumble™9.12.2022 06:30:00 EET | Press release

Get ready to team up and throw down, because Crash and his friends (and foes) are back, and this time there will be some unexpected, fur-ocious competition! In development by the talented team at Toys for Bob who brought fans the acclaimed Crash Bandicoot™ 4: It’s About Time™, Crash Team Rumble ™ is an all-new 4v4, team-based online multiplayer video game set in Crash Bandicoot’s vibrant and zany universe. Published by Activision Publishing, Inc., Crash Team Rumble will release on PlayStation®5, PlayStation®4, Xbox® Series X/S and Xbox One® in 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005292/en/ Crash Team Rumble Gameplay Screenshot (Photo: Business Wire) In Crash Team Rumble , fans can play as Crash, Dingodile, and a host of other friends and frenemies, each of which has their own distinct power, personality, and playstyle, as they compete across wild and varied arenas in 4v4 team-based online multiplayer a

Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer9.12.2022 02:00:00 EET | Press release

Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 70% of breast cancer tumors are considered HR positive and HER2 low or negative.1 For patients with HR positive, HER2 low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine the

TreviPay Acquires Apruve9.12.2022 01:45:00 EET | Press release

TreviPay, a leader in global B2B payments and invoicing solutions, today announced the signing of a definitive agreement to acquire payment platform Apruve. Apruve offers a robust suite of payment solutions for global enterprises that will complement and expand on TreviPay’s existing order-to-cash technology offerings, merchant invoicing solutions, and the geographical reach of TreviPay’s existing B2B networks. TreviPay has experienced unprecedented demand from global enterprise buyers and sellers resulting in 30% organic growth in 2022, and this acquisition furthers TreviPay's plans to expand its order-to-cash technology offerings and B2B payment network. This acquisition builds on TreviPay’s recent purchase of Baton Financial Services. “TreviPay provides payment and invoicing solutions for a number of leading manufacturers and OEMs; the acquisition of Apruve will accelerate our advancement in the technology manufacturing vertical and expand our geographic reach into key Asian markets

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy9.12.2022 00:05:00 EET | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabometyx® (cabozantinib) in combination with atezolizumab (Tecentriq®) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy. Howard Mayer, M.D., Executive Vice President, Head of Research and Development at Ipsen, said: “The results from the CONTACT-01 clinical trial have shown the challenge of treating NSCLC patients after prior lines of treatment have failed. While the findings of the study have not met the primary endpoint in this setting, we remain confident in the clinical efficacy of cabozantinib alone and in combination with another treatment in existing indications in difficult-to-treat tu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom